Overview

A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to evaluate the efficacy and safety of BR1015 Combination therapy group in comparison with Fimasartan monotherapy group at Week 8 for essential hypertension patients who do not adequately responded by Fimasartan 30 mg
Phase:
Phase 3
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Indapamide